Related Experiment Video

Updated: Mar 6, 2026

Application of Hemostatic Devices in Laparoscopic Hepatectomy
04:23

Application of Hemostatic Devices in Laparoscopic Hepatectomy

Published on: April 19, 2022

2.9K

Impact of Comorbidity and Prescription Drugs on Haemorrhage in Cholecystectomy

J Strömberg1, G Sandblom2

  • 1Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, Stockholm, Sweden. stromberg10000@gmail.com.

World Journal of Surgery
|March 8, 2017
PubMed

Insights

Patient comorbidities like heart disease and diabetes increase bleeding risk after cholecystectomy. Perioperative bleeding also raises mortality and bile duct injury risks.

Area of Science:

  • Surgery
  • Gastroenterology
  • Clinical Risk Management

Background:

  • Cholecystectomy is a common surgical procedure.
  • Hemorrhagic complications can occur post-cholecystectomy.
  • Identifying risk factors is crucial for patient safety.

Purpose of the Study:

  • To analyze patient-related risk factors for hemorrhagic complications after cholecystectomy.
  • To investigate the impact of specific medications on bleeding risk.
  • To assess the consequences of perioperative hemorrhage.

Main Methods:

  • Utilized data from the Swedish GallRiks register (2005-2015).
  • Linked GallRiks data with National Patient Register and Prescribed Drug Register.
  • Employed multivariable regression and Kaplan-Meier analysis to assess hemorrhage risk and survival rates.

Main Results:

  • Over 94,000 patients analyzed; 0.8% experienced perioperative and 1.3% post-operative hemorrhage.
  • Comorbidities including cerebrovascular disease, myocardial infarction, kidney disease, heart failure, diabetes, peripheral vascular disease, and obesity significantly increased hemorrhage risk.
  • Tricyclic antidepressants and dipyridamole showed a trend towards increased perioperative hemorrhage risk, though not statistically significant after correction.

Conclusions:

  • Patient comorbidities significantly elevate hemorrhage risk pre-cholecystectomy.
  • Perioperative bleeding is linked to increased 1-year mortality and bile duct injury.
  • Risk factor assessment is vital for optimizing patient outcomes.
Abstract

More Related Videos

Intraoperative Video Consultation Following Bile Duct Transection Facilitates Direct OR Transfer for Robotic Hepaticojejunostomy at Tertiary Center07:48

Intraoperative Video Consultation Following Bile Duct Transection Facilitates Direct OR Transfer for Robotic Hepaticojejunostomy at Tertiary Center

Published on: January 9, 2026

943
Application of Laparoscopic Ultrasonography in Primary Choledochal Suture during Combined Two-lens Surgery04:03

Application of Laparoscopic Ultrasonography in Primary Choledochal Suture during Combined Two-lens Surgery

Published on: March 28, 2025

609

Related Concept Videos

Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
148
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
304
Factors Influencing Drug Absorption: Disease States and Pharmacology01:25

Factors Influencing Drug Absorption: Disease States and Pharmacology

Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
1.6K
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
700
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
867
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K